WIRB 20171347
#16684511.0

Now Enrolling Patients

Observational Study of the Effect of VarIthEna® on Wound Healing in the Treatment of Venous Leg Ulcers Resulting from Chronic Venous Insufficiency



Varithena® registry is now enrolling:

- Do you have a history of varicose veins and a venous leg ulcer (wound)?
- Have you had it for at least 3 months?

You might qualify for a clinical study and could be treated with Varithena®.

To find out more information, you can go to venouslegstudy.com or contact a local study physician at:

The Venous Institute of Buffalo

Phone: (716) 877-7000

4927 Main St. Suite 400
Amherst, NY 14226

www.VenousInstitute.com

Sponsor: Provensis Ltd, A BTG International group company

BTG

FDA CLEARED INDICATIONS: FDA CLEARED INDICATIONS: Varithena® (polidocanol injectable foam) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. Instructions for Use, including warnings, precautions, potential complications, and contraindications can be found at www.btg-ei.com/us-US/
Varithena, VariVein and HASTI are registered trademarks of Provensis Ltd, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd.
©2017 Biocompatibles, Inc., a BTG International group company • NA-VAR-2017-0940